Cargando…

The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer

Although cyclin-dependent kinase (CDK) 4/6 inhibitors have exhibited remarkable results for patients with estrogen receptor (ER)–positive breast cancer in clinical trials, the mechanism of CDK4/6 inhibitor resistance remains unclear. Thus, this study aimed to investigate the mechanism of CDK4/6 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iida, Masafumi, Nakamura, Misato, Tokuda, Emi, Toyosawa, Daichi, Niwa, Toshifumi, Ohuchi, Noriaki, Ishida, Takanori, Hayashi, Shin-ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690670/ https://www.ncbi.nlm.nih.gov/pubmed/31448056 http://dx.doi.org/10.18632/oncotarget.27127

Ejemplares similares

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Randomized Controlled Trial on Effectiveness of Ultrasonography Screening for Breast Cancer in Women Aged 40–49 (J-START): Research Design
por: Ohuchi, Noriaki, et al.
Publicado: (2011)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Smoking and survival after breast cancer diagnosis in Japanese women: A prospective cohort study
por: Kakugawa, Yoichiro, et al.
Publicado: (2015)

Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment
por: Sakurai, Minako, et al.
Publicado: (2017)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Ribociclib in newly diagnosed hepatitis B infection: A case report
por: Di Costanzo, Fabrizio, et al.
Publicado: (2023)

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
por: Al-Shdefat, Ramadan, et al.
Publicado: (2023)

Participants’ understanding of a randomized controlled trial (RCT) through informed consent procedures in the RCT for breast cancer screening, J-START
por: Shiono, Yoko Narikawa, et al.
Publicado: (2014)

TP53 signature diagnostic system using multiplex reverse transcription–polymerase chain reaction system enables prediction of prognosis of breast cancer patients
por: Takahashi, Shin, et al.
Publicado: (2021)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017)

Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review
por: Badran, Omar, et al.
Publicado: (2023)

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
por: Buehler, Anna Maria, et al.
Publicado: (2022)

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation
por: Jhan, Jyun-Yan, et al.
Publicado: (2023)

Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging
por: Gonda, Kohsuke, et al.
Publicado: (2015)

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2017)

Ribociclib-Related Stevens–Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review
por: López-Gómez, Victoria, et al.
Publicado: (2019)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
por: Loke, Lydia, et al.
Publicado: (2020)

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells
por: Zhang, Lei, et al.
Publicado: (2022)

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
por: Schuler, Martin, et al.
Publicado: (2022)

Quantitative diagnosis of HER2 protein expressing breast cancer by single‐particle quantum dot imaging
por: Miyashita, Minoru, et al.
Publicado: (2016)

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations
por: Samant, Tanay S., et al.
Publicado: (2017)

Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
por: Wong, Chi-Hang, et al.
Publicado: (2018)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Ribociclib in Kombination mit endokriner Therapie verbessert Überleben von prä-/perimenopausalen Mammakarzinom-Patientinnen
por: Krug, David, et al.
Publicado: (2020)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
por: Alotaibi, Wedad H., et al.
Publicado: (2022)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib
por: Menteşoğlu, Dilek
Publicado: (2023)

Increased centrosome number in BRCA‐related breast cancer specimens determined by immunofluorescence analysis
por: Watanabe, Gou, et al.
Publicado: (2018)

Evaluation of Adjunctive Ultrasonography for Breast Cancer Detection Among Women Aged 40-49 Years With Varying Breast Density Undergoing Screening Mammography: A Secondary Analysis of a Randomized Clinical Trial
por: Harada-Shoji, Narumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_euece8rhr6s3qn3lncja1dli5t